Boston Scientific Corp (NYSE:BSX) fell over 6% Wednesday after management lowered its full-year guidance during a presentation at Bernstein.

Boston Scientific (BSX) stock hits a 52-week low as the company highlights a slowdown in demand for its WATCHMAN cardiac ...

Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today ...

The medical device maker flags a drop in stand-alone procedures for its Watchman heart implant, hitting its near-term growth ...

By Kamal Choudhury May 27 (Reuters) - Boston Scientific shares fell about 12% on Wednesday to their lowest in more than two ...

Boston Scientific shares sank to their lowest in over two years on Wednesday, after the medical device maker warned it was ...

WATCHMAN's 19% growth and trial wins bolster Boston Scientific's push to expand its addressable market from 5M to 20M ...

NATICK, Mass., European regulators have approved an expanded indication for the Boston Scientific Corporation WATCHMAN ® Left Atrial Appendage (LAA) Closure Device. The new indication offers patients ...

Boston Scientific's Watchman antistroke device won overwhelming backing from an FDA panel of experts.--Courtesy of Boston Scientific After an up-and-down development ...

Boston Scientific's Watchman proved more effective than warfarin in a follow-up study.--Courtesy of Boston Scientific Boston Scientific's ($BSX) Watchman is more ...

On Friday, Boston Scientific announced that FDA has approved the Watchman left atrial appendage closure device, a heart device that while novel was initially rejected. The device is intended for ...